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Abstract
CLN5 is a soluble lysosomal protein with unknown function. Mutations in CLN5 lead to neuronal ceroid lipofuscinosis, a
group of inherited neurodegenerative disorders that mainly affect children. CLN5 has eight potential N-glycosylation sites
based on the Asn-X-Thr/Ser consensus sequence. Through site-directed mutagenesis of individual asparagine residues to
glutamine on each of the N-glycosylation consensus sites, we showed that all eight putative N-glycosylation sites are
utilized in vivo. Additionally, localization studies showed that the lack of N-glycosylation on certain sites (N179, N252, N304,
or N320) caused CLN5 retention in the endoplasmic reticulum, indicating that glycosylation is important for protein folding.
Interestingly, one particular mutant, N401Q, is mislocalized to the Golgi, suggesting that N401 is not important for protein
folding but essential for CLN5 trafficking to the lysosome. Finally, we analyzed several patient mutations in which N-
glycosylation is affected. The N192S patient mutant is localized to the lysosome, indicating that this mutant has a functional
defect in the lysosome. Our results suggest that there are functional differences in various N-glycosylation sites of CLN5
which affect folding, trafficking, and lysosomal function of CLN5.
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Introduction
Neuronal ceroid lipofuscinoses (NCLs), also known collectively
as Batten disease, are a group of progressive neurodegenerative
disorders that predominantly affect children. NCLs are charac-
terized by mental retardation, impediment of motor capabilities,
loss of vision, and premature death [1]. With different ages of
onset and progression, several forms of NCL have been
characterized as infantile (INCL), late infantile (LINCL), juvenile
(JNCL), and adult NCL (ANCL) [2]. NCL is classified as a
lysosomal storage disorder based on the buildup of autofluorescent
lipopigments, lipofuscin-like ceroids, in the lysosomes of neurons as
well as some other cell types [3,4]. The lipopigments consist of
proteins, lipids, and carbohydrates. Depending on the subtype of
the disease, the majority of the accumulated proteins are either the
subunit C of mitochondrial ATP synthase [5] or saposins A and D
[6]. Even though the proteins underlying NCLs are ubiquitously
expressed, neuronal cells are by far the most affected cell type by
these dysfunctional NCL proteins [7].
CLN5 is one of the 13 genes that have been identified to be
associated with NCLs (NCL resource, University College London).
CLN5 mutations were initially reported to be limited to Finnish
and other Northern European populations [8], but a recent study
has identified CLN5 mutations in a variety of ethnic backgrounds
[9]. CLN5 disease is mostly associated with the late infantile form
of NCLs, although juvenile and adult forms have been identified as
well [9,10]. Human CLN5 consists of 407 amino acids with an N-
terminal signal sequence that is cleaved after entering the ER. It
does not share any apparent homology with other proteins. CLN5
is a soluble protein [11] despite the presence of a predicted
transmembrane segment. It localizes to the lysosomal compart-
ment [11,12]. The exact function of CLN5 protein is unclear. A
recent study reported that CLN5 is essential for the recruitment of
retromer, which in turn is responsible for the sorting and recycling
of lysosomal receptors [13]. However, this finding is inconsistent
with the soluble lysosomal protein properties of CLN5. CLN5 has
also been suggested to function as a regulator of dihydroceramide
synthase [14,15].
CLN5 has eight putative N-glycosylation sites based on the
consensus sequence of N-X-T/S. Treatment of CLN5 with
Endoglycosidase H (Endo H) to remove high mannose type N-
linked glycans resulted in a reduction in size from ,60 kDa to
,35 kDa, indicating that CLN5 is heavily glycosylated [11].
However, it is not known which of these eight sites are utilized. In
another NCL protein, tripeptidyl-peptidase I (TPP I, CLN2
protein), there are five consensus N-glycosylation sites which are
all utilized in vivo [16]. Of these five, only one residue, N286, seems
to have a major effect on its lysosomal localization and maturation
processing which subsequently affects enzyme activity. Mutation of
this site was identified in some patients (N286S) [17]. Missing
glycosylation on this residue causes TPP I to be retained in the ER
[16,18].
Soluble proteins destined to the lysosome generally contain one
or more Mannose-6-Phosphate (Man-6-P) residues on their N-
linked oligosaccharides. Man-6-P receptors (MPRs) at the trans
Golgi network (TGN) recognize these moieties and facilitate
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sorting and transportation of the Man-6-P tagged proteins to the
endosome and subsequently to the lysosome [19]. Interestingly,
CLN5 is capable of utilizing MPR-independent pathway(s) to
reach the lysosomes in the absence of MPRs [12]. While a
proteomic study using mass spectrometry analysis to look for Man-
6-P lysosomal proteins has identified Man-6-P sites at N401 and
possibly at N320 and/or N330 of human CLN5 [20], there is no
definitive data that proves the involvement of these residues in
MPR-dependent transport of CLN5.
Three patient mutations in CLN5 are particularly interesting
because they point toward an important role for N-glycosylation in
CLN5. One mutant, D279N, introduces a consensus N-glycosyl-
ation site, while the other two, N192S and Y392X, lose a potential
N-glycosylation site. This prompted us to systematically analyze
the importance of CLN5 glycosylation.
In this study, we use site-directed mutagenesis to create mutants
for each of the eight predicted N-glycosylation sites and confirm
their glycosylation states in vivo. We show that all eight consensus
sites are used in vivo. Loss of N-glycosylation at specific sites leads
to mislocalization of CLN5 either to the ER or the Golgi, whereas
other mutants show little mislocalization and are able to reach the
lysosome.
Materials and Methods
Reagents
Cell culture media and reagents were purchased from Gibco
and Hyclone. Endoglycosidase H (Endo Hf), peptide-N-glycosi-
dase F (PNGase F), and other molecular cloning reagents were
purchased from New England Biolabs (NEB). The TransIT-LT1
transfection reagent was purchased from Mirus Bio. Cyclohexi-
mide was purchased from Fisher Scientific. Tunicamycin was
purchased from Enzo Life Sciences. EGFP-Rab5A Q79L was a
gift from Qing Zhong (Addgene plasmid 28046; [21]). Sapphire
Coomassie Blue kit was obtained from Gold Biotechnology.
Antibodies
Mouse monoclonal antibodies used in this study were against
the Myc epitope (9E10, hybridoma cell line from ATCC (CRL
1729)). Rabbit polyclonal antibodies used in this study were
against calnexin (Genscript), Grasp65 (Pierce), and Lamp2
(Pierce). HRP-conjugated secondary antibodies for Western
blotting were purchased from Jackson Laboratory. Secondary
antibodies conjugated to Alexa Fluor 488, 546, and 633 were
purchased from Molecular Probes.
Site-directed Mutagenesis
The cDNA encoding wild type (wt) CLN5 was purchased from
GeneCopoeia and cloned into pcDNA3.1/Myc-His(2)A using
EcoRI and BamHI restriction sites. To generate individual N-
glycosylation mutants, the codon for Asn in the consensus
sequence for N-glycosylation was mutated to a codon for Gln
using phusion-based site-directed mutagenesis (NEB). The cDNAs
containing the single mutations for the N-glycosylation sites served
as templates for creating multiple N-glycosylation mutants. All
constructs were confirmed by sequence analysis.
Cell Culture and Transfections
HeLa cells (ATCC CCL-2) were grown and maintained in
Dulbecco’s modified eagle medium (DMEM) supplemented with
10% fetal bovine serum, glutamax, HEPES, and gentamicin at
37uC in a humidified incubator with 5% CO2. Cells were seeded
in a culture dish with or without coverslips 24 h before
transfection. Cells were transiently transfected using Mirus
TransIT-LT1 transfection reagent according to manufacturer’s
protocol. 24 h after transfection, cells were either fixed for
immunofluorescence staining or collected for further biochemical
analyses. For cycloheximide treatments (50 mg/ml) in immunoflu-
orescence studies, cycloheximide was added to the cells 2 h prior
to fixation. For cycloheximide treatment in biochemical studies,
cell medium was replaced with Gibco OPTI-MEM reduced serum
medium containing 50 mg/ml cycloheximide 20 h after transfec-
tion. Cells were collected at 0, 2, and 4 h post treatment, and
media were collected at 2 and 4 h post treatment. Medium
samples were then concentrated with spin columns (Pierce
concentrator, 10 K MWCO) before proceeding to protein gels.
Immunofluorescence Microscopy
Cells were fixed with 4% formaldehyde for 10 min at room
temperature. Blocking, permeabilization, antibody incubations,
and washes were done using blocking solution (10% fetal calf
serum, 0.1% saponin, and 0.02% sodium azide in PBS). The cells
were imaged using a Zeiss LSM-5 PASCAL laser scanning
confocal microscope.
Deglycosylation Experiments
Deglycosylation of samples with Endo H or PNGase F was
performed according to manufacturer’s recommendations. Diges-
tion with the enzymes was carried out for 3 h at 37uC. For
tunicamycin treatments (1 mg/ml), the chemical was added to cells
at the time of transfection.
Results
N-glycosylation of CLN5 in vivo
Human CLN5 protein consists of 407 amino acids with eight
putative N-glycosylation sites located at Asn 179, 192, 227, 252,
304, 320, 330, and 401 (Fig. S1). To determine which of these
eight N-glycosylation sites is (are) utilized in vivo, we eliminated
each of these potential sites in CLN5 by substituting a Gln codon
for the Asn codon. We also recreated a patient mutation D279N
[8], which results in an additional N-glycosylation site at residue
279. Wt CLN5 migrated on gel as a species with a molecular
weight of ,55 kDa. Each of the eight N to Q mutants showed an
increased mobility in gel corresponding to a ,2.5 kDa reduction
in molecular weight as compared to wt. This shows that each of
the eight putative N-glycosylation sites is used in vivo (Fig. 1A). The
D279N mutant, as has been observed before [12], showed a
retarded migration on gel equivalent to a ,2.5 kDa increase in
molecular weight as compared to the wt CLN5. This is consistent
with the presence of an additional glycosylation site on the D279N
mutant. We also noticed that there were slight mobility differences
between the various mutants, which might indicate that not all of
the oligosaccharides are modified in an identical fashion. The
Western blots were stained with Coomassie blue to show equal
sample loading in each lane (Fig. S2).
In addition to mutating the N to a Q for the N192 mutant, we
also changed this amino acid to an S to replicate a mutant form
that has been isolated from a patient [9]. The N192S showed a
similar reduction in size as the N192Q mutant (Fig. 1B), indicating
that it is the abrogation of N-glycosylation that changes the
mobility of the protein and not some unanticipated behavior by an
N to Q mutation in general. Thus, our findings confirmed that all
of the eight potential N-glycosylation sites in CLN5 are used in vivo
and removing any one of these sites results in a reduction of
,2.5 kDa in size. We also created a double mutant containing
both N-glycosylation site mutations of N192Q and N330Q to see if
there is indeed an additive effect from the combined mutations. As
N-Glycosylation of Human CLN5
PLOS ONE | www.plosone.org 2 September 2013 | Volume 8 | Issue 9 | e74299
expected, the double mutant ran ,2.5 kDa lower than the single
mutant and ,5 kDa lower than wt CLN5 (Fig. 1C).
Subcellular Localization of CLN5 N-glycosylation Mutants
CLN5 is a lysosomal luminal protein. For proteins localized in
the lysosomes, glycosylation can be important for proper folding in
the ER, trafficking to the lysosomes, or providing stability and/or
functionality in the lysosomes [22,23]. Thus, if glycosylation on a
specific site is crucial for folding, the lack of such glycosylation will
result in a misfolded protein that is retained in the ER and
targeted for degradation [24]. On the other hand, if a particular
glycosylation is essential for targeting the protein to the endosomes
and subsequently to the lysosome, the absence of this modification
will most likely result in secretion of the protein or accumulation in
the Golgi [25]. If the glycosylation mutant can reach the lysosome,
it suggests that that specific glycosylation is not critical for folding
and trafficking. In such cases, glycosylation might be either
redundant or important for the function in the lysosome.
Therefore, to assess the function of glycosylation on different sites
in CLN5, we examined subcellular localization of each N-
glycosylation mutant. HeLa cells were transiently transfected with
CLN5. Two hours prior to fixation, cells were treated with
cycloheximide to block further protein synthesis in order to ensure
minimal amounts of ‘‘en route’’ proteins distorting the analysis.
Confocal microscopy showed that the N192Q and N227Q
mutants colocalized partially with the lysosomal marker Lamp2,
similar to wt CLN5 (Fig. 2, A and B). N179Q, N252Q, N304Q,
and N320Q did not colocalize with Lamp2 (data not shown).
Instead, these CLN5 mutants colocalized with an ER marker,
calnexin (Fig. 2C). N330Q, on the other hand, can be observed in
the ER as well as in lysosomes (Fig. 2D). The N401Q mutant
colocalized with the Golgi marker, Grasp65 (Fig. 2E). These
findings indicate that some of the N-glycosylation sites (N179, 252,
304, 320, and 330) are crucial for the folding of CLN5, as lack of
N-glycosylation at any of these sites resulted in CLN5 protein
retention in the ER. The N330Q mutation has a milder effect on
overall folding, as it partially localized to the lysosome. N401 is
essential for trafficking from the Golgi to the lysosome, whereas
N192 and N227 seem to have no apparent roles in the proper
folding or trafficking of CLN5.
Because wt CLN5 and several mutants partially localized to the
lysosome, there might be some ambiguity about the similarity in
their localization. Therefore, we decided to manipulate the system
by co-expressing different N-glycosylation mutants in combination
with a mutant form of Rab5A (EGFP-Rab5A Q79L) [21]. The
small GTPase Rab5 gives identity to early endosomes [26] and has
been used as an early endosome marker. The mutant Rab5A
Q79L has defective GTPase activity, resulting in endosome fusion
and the formation of enlarged endosomes [27]. As a consequence,
proteins destined to reach the lysosomes will accumulate within
these enlarged endosomes (luminal proteins) or on the limiting
membrane of the enlarged endosomes (transmembrane proteins).
HeLa cells were co-expressed with EGFP-Rab5A Q79L and wt
CLN5 or N-glycosylation mutants followed by 2 h of cyclohex-
imide chase before fixation. The lysosomal mutants (N192Q and
N227Q) and wt CLN5 were largely localized inside of the enlarged
endosomes (Fig. 3A), indicating that they normally reside in the
endosome/lysosome. The ER mutants (N179Q, N252Q, N304Q,
and N320Q) did not localize in the proximity of the enlarged
endosomes but instead showed a pattern consistent with ER
localization (Fig. 3B). N401Q did not localize inside the enlarged
endosomes nor did it show a typical ER pattern. When staining for
Grasp65, we observed that Golgi morphology was not affected by
Rab5A Q79L expression, and the N401Q mutant colocalized with
Grasp65 very well (Fig. 3C). N330Q, again, can be seen equally
either inside or outside the enlarged endosomes (Fig. 3D). These
results are consistent with our earlier colocalization data. Like wt
CLN5, N192Q and N227Q mutants can reach the endosome/
lysosome, without any ambiguity. However, the majority of the
other mutants are either retained in the ER (N179Q, N252Q,
N304Q, and N320Q) or accumulated in the Golgi network
(N401Q). We noted that a small population of all ER localized
mutants escaped from the ER and can be seen in the enlarged
endosomes. This is probably due to overexpression of the proteins.
Deglycosylation Studies of CLN5
It has been reported that some glycans on CLN5 are
Endoglycosidase H (Endo H) sensitive, and digestion with Endo
H results in a reduction of the CLN5 molecular weight [11]. After
we digested CLN5 with Endo H, all the single mutants (including
D279N) and wt CLN5 migrated on gel to the same size of
,35 kDa (Fig. 4A). This further confirms that the difference of
,2.5 kDa between the wt and single glycosylation site mutants
was due to N-glycosylation since removal of oligosaccharide chains
eliminated the size difference between wt and the mutants. This
also implies that all N-glycans on CLN5 are Endo H sensitive, as
Endo H digestion on the mutants did not reveal any resistant
Figure 1. All eight putative N-glycosylation sites of CLN5 are
utilized in vivo. HeLa cells were transiently expressing the various N-
glycosylation mutants of CLN5 as indicated. The whole cell lysates were
collected 24 h post transfection and analyzed by Western blotting. (A)
wt CLN5, D279N, and eight single N-glycosylation site-deleted mutants
as indicated. (B) Comparing N192Q and N192S (patient mutation)
migration on gel. (C) Comparing migration on gel of single and double
N-glycosylation site mutants. Equal amount of lysates was loaded onto
each well. The mouse monoclonal anti-Myc antibody was used to
detect CLN5.
doi:10.1371/journal.pone.0074299.g001
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chains. The difference between the size of undigested wt CLN5
and Endo H digested wt CLN5 was ,20 kDa (Fig. 1A and 4A),
which can be explained by the eight oligosaccharide chains, each
of ,2.5 kDa in size.
To investigate N-glycosylation modification further, we digested
CLN5 with peptide N-glycosidase F (PNGase F). Endo H cuts
after the first N-acetylglucosamine of the oligosaccharide chain on
Asn, thus leaving one sugar moiety on Asn. In contrast, PNGase F
cuts immediately after the Asn and does not leave any sugar
moiety. When we treated wt CLN5 with PNGase F, we observed
faster migration of CLN5 as compared to Endo H treatment,
consistent with eight N-acetylglucosamine moieties having been
further removed (Fig. 4B). We also examined the effect of
tunicamycin treatment. Tunicamycin prevents the first step of N-
glycosylation in the ER and as a consequence, the CLN5
synthesized in the presence of tunicamycin will have no glycans
Figure 2. Subcellular localization of CLN5 N-glycosylation mutants. Confocal microscopy analysis of cells transiently expressing N-
glycosylation mutants of CLN5. HeLa cells were seeded on glass coverslips and transfected with wt CLN5 or mutants. The cells were treated with
cycloheximide for 2 h prior to fixation. Different antibodies were used to label specific organelles (A), (B) and (D) Lamp2 for the lysosomes, (C) and (D)
Calnexin for the ER, (E) Grasp65 for the Golgi. Cln5 mutants are as indicated. The mouse monoclonal anti-Myc antibody was used to detect CLN5.
Original magnification, 1,0006 . Bars, 5 mm.
doi:10.1371/journal.pone.0074299.g002
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attached. Interestingly, we observed an even faster migrating
species of CLN5 (,32 kDa) than those resulting from PNGase F
treatment (Fig. 4B). Since tunicamycin treatment causes CLN5
retention in the ER (data not shown), any further modification that
takes place in organelles beyond the ER cannot occur.
Stability of CLN5 Deficient in N-glycosylation
In our immunofluorescence studies, we noticed that wt CLN5
and mutants that reached the lysosome had lower signal intensity
than the ER CLN5 mutants after a 2 h cycloheximide chase. This
was surprising, as it could suggest that lysosome-localized CLN5
has a shorter half-life. To test this, we performed transient
transfections, replaced the media after 20 h, and directly treated
the cells with cycloheximide for 0, 2, or 4 h. Since we, as well as
others [11], have detected secreted CLN5 in the media, we also
collected the media at 2 and 4 h time points. For the lysosome
localized CLN5, the protein levels decrease in the cell pellets with
increasing time of cycloheximide chase (Fig. 5, wt, N192Q, and
N227Q), consistent with our initial observations of reduced
fluorescence. At the same time, we observed a concomitant
increase in CLN5 protein levels in the media. Similarly to the
lysosome localized CLN5, a large portion of the Golgi localized
mutant, N401Q, can be observed in the media after a 4 h
cycloheximide chase (Fig. 5, N401Q). This suggests that the
Figure 3. Accumulation of lysosomal-localized CLN5 in Rab5A Q79L-induced enlarged endosomes. HeLa cells were seeded on glass
coverslips and double transfected with EGFP-Rab5A Q79L and wt CLN5 or N-glycosylation mutants as indicated. The cells were chased with
cycloheximide for 2 h prior to fixation. Localization of (A) CLN5 wt, N192Q, and N227Q, (B) N179Q, N252Q, N304Q, and N320Q, (C) N401, (D) N330Q in
Rab5A Q79L expressing cells. Original magnification, 1,0006 . Bars, 5 mm.
doi:10.1371/journal.pone.0074299.g003
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reduced fluorescence observed is not due to short half-life or
protein degradation, but rather the secretion of CLN5 to the
media. This is in agreement with a previous finding that wt CLN5
is stable in cells [12]. In contrast to the lysosome- and Golgi-
localized CLN5 proteins, there was much less CLN5 detected in
the media for the ER-localized mutants (Fig. 5, N179Q, N252Q,
N304Q, and N320Q). All of the ER mutants showed some
decrease in protein levels detected in the cell pellet samples over
time, but with the lack of significant increase in CLN5 protein
levels in the media, it is most likely that the decrease is due to
protein degradation in the cell. Quantified representation of this
data is shown in Fig. S3.
Based on the localization and stability assays, we can categorize
N-glycosylation of CLN5 into three groups (Table 1). In the first
group, glycosylation is involved in folding of the protein, without
such modification, CLN5 is retained in the ER. In the second
group, glycosylation is involved in endosome/lysosome trafficking.
Without such signal, CLN5 is accumulated in the Golgi
temporarily and then transported towards the plasma membrane
for secretion. In the third group, glycosylation does not have a
direct role in folding and trafficking but could instead be important
for CLN5 lysosomal function or have some redundant role.
Subcellular Localization and Stability of CLN5 Patient
Mutants
With the role of CLN5 glycosylation categorized into three
functional groups, we now wanted to assign the patient mutants
discussed earlier to specific categories. As shown in Fig. 6A, upon
co-expression with Rab5A Q79L, the D279N and Y392X mutants
did not colocalize with the enlarged endosomes but instead
showed localization consistent with presence in the ER. Therefore,
we categorize the D279N and Y392X mutants in the group of
mutants that cannot fold properly and thus are retained in the ER.
As might be expected, based on the N192Q mutant reaching the
lysosome, the N192S mutant was able to reach the enlarged
endosomes. Thus, the detrimental effect of this mutation is unlikely
to be caused by misfolding or improper localization, but most
likely due to a functional defect after transportation to the
lysosome. This is the first CLN5 patient mutation that has been
convincingly shown to localize mostly in the lysosome (see
discussion). We also analyzed the possible secretion of these
patient mutants using cycloheximide chase and biochemical
analyses of cell pellets and media as in Fig. 5 (Fig. 6B). Of the
three patient mutants studied, only N192S showed significant
protein secretion into the media, which is consistent with the
behavior of other lysosome-localized CLN5 mutants. The other
patient mutants, which are localized to the ER, remained in the
cell pellets. It was additionally notable that the Y392X mutant was
less stable than D279N. Quantification data is shown in Fig. S3.
Discussion
While the function of CLN5 is not known, it is clear that several
modifications occur during and after translation. Supported by
experimental data [12] and sequence prediction (SignalP 4.1) [28],
it is evident that the N-terminus of CLN5 undergoes signal peptide
cleavage in the ER during co-translation import (see alignment in
Fig. S1). Another major modification is N-glycosylation. In this
report, we show that all eight putative N-glycosylation sites of
human CLN5 are utilized in vivo. Seven of the eight N-
glycosylation sites are conserved among mammalian species
(orange box in Fig. S1). The last glycosylation site, N401, is not
present in Mus musculus and Rattus norvegicus (green box in Fig. S1).
Interestingly, our data demonstrated that N401 glycosylation is
essential for lysosomal localization of human CLN5. Without this
site, CLN5 is accumulated in the Golgi temporarily and then
secreted into the media. This suggests that the Man-6-P
modification on N401 is the major determinant of human
CLN5 lysosomal transport via MPR-dependent route. Consistent
with this, a large-scale proteomic study identified a Man-6-P
moiety on N401 of human CLN5 [20]. Besides N401 residue,
N320 and N330 of human CLN5 were identified as tentative
Man-6-P containing residues [20]. However, our results show that
N401Q, with only one glycosylation site removed, was unable to
transport to lysosomes, suggesting that either only this site contains
a Man-6-P moiety or that other Man-6-P moieties on N320 or
N330 are not determinants for MPR-dependent transport for
CLN5. N-glycosylation on N320 is essential for proper folding, as
N320Q is retained in the ER. Due to retention in the ER of the
mutant form, we cannot evaluate the role of N320 in the TGN or
endosome trafficking. Even if N320 or N330 residue is tagged with
Man-6-Ps in the N401Q mutant, the signal does not suffice for
targeting CLN5 to the lysosome because the N401Q mutant is
mislocalized.
Intriguingly, using MPRs-deficient MEF cells, mouse and
human CLN5 have been shown to reach lysosomes in an MPR-
independent manner [12]. As mentioned earlier, mouse CLN5
lacks a residue equivalent to the N401 glycosylation residue found
in humans. This may suggest that mouse CLN5 is transported to
lysosomes via an MPR-independent pathway. Consistent with this,
in mouse CLN5, no specific Man-6-P containing residue was
identified [20,29]. However, mouse CLN5 has still been found in
MPR affinity purified cell and/or serum samples in several studies
[20,29,30]. Based on our findings, it is harder to explain why
Figure 4. Endo H sensitivity and deglycosylation studies of
CLN5. (A) Whole cell lysates transiently expressing N-glycosylation
mutants were digested with Endo H enzyme and analyzed by Western
blotting. (B) Western blotting of uncut, Endo H, or PNGase F treated
whole cell lysates expressing wt CLN5, as well as whole cell lysates from
CLN5 transfection in the presence of tunicamycin. Equal amount of
lysates was loaded onto each well. The mouse monoclonal anti-Myc
antibody was used to detect CLN5.
doi:10.1371/journal.pone.0074299.g004
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human CLN5 can also be transported to lysosomes in MPRs-
deficient MEF as described in Schmeidt et al. 2010 studies.
From deglycosylation studies, we found that the size of CLN5
synthesized in the presence of tunicamycin is smaller than PNGase
F digested CLN5. Three possibilities can potentially explain this.
First, there might be a PNGase F resistant glycan on CLN5.
However, this is unlikely since PNGase resistant glycans have been
found mainly in plants and some insect species [31]. Second, the
size difference could be due to polypeptide property changes after
PNGase F treatment. This is possible as PNGase F digestion not
only removes N-glycans but also modifies the glycan-attached
asparagine residue to aspartic acid, whereas tunicamycin treat-
ment does not change CLN5 amino acid residues. The third and
most plausible explanation is that there are other modifications on
CLN5 besides N-glycosylation. However at this point, we do not
know what type(s) of modification causes the molecular weight
difference between PNGase F and tunicamycin treated CLN5.
Further analysis will be required to address this question.
The localization of patient mutant Y392X has been controver-
sial. The introduction of a premature stop codon results in the
elimination of the N401 glycosylation site as well as 15 amino
acids. One study showed that the Y392X mutant can reach the
Golgi [11], consistent with the lack of N401 glycosylation.
However, another study showed that this mutant mainly localizes
to the ER [12]. Our immunofluorescence data confirm the latter.
This also indicates that the last 15 amino acids have important
roles in the overall folding besides containing the N401 dependent
lysosomal trafficking signal. Clearly, the ER retention of patient
mutant forms Y392X and D279N can explain the lack of
functional CLN5 in these patients, as these mutant forms never
reach their intended destination. More intriguingly, from a
functional perspective, is the N192S patient mutant. Thus far,
all other patient mutant forms of CLN5 characterized are
mislocalized, including R112P, R112H, E253X, D279N [12]
(and our study), L358Afs*4, W379C [32], Y392X [11,12] (and our
study). One study, however, did show D279N and Y392X to be
localized to the lysosome, similar to the wt CLN5 [33]. However,
the images were over-exposed and all the patient mutants were
localized to the lysosome in that study. These findings are
inconsistent with the majority of the literature cited above. Here
we used several approaches to show that the N192S mutant
Figure 5. Stability of N-glycosylation deficient CLN5 proteins. HeLa cells were transfected with wt CLN5 or N-glycosylation mutants as
indicated for 20 h after which cycloheximide chase was performed for 0, 2, and 4 h. Cell pellets from 0, 2, and 4 h and medium samples from 2 and
4 h are shown. No samples were loaded in lanes labeled (2). The mouse monoclonal anti-Myc antibody was used to detect CLN5.
doi:10.1371/journal.pone.0074299.g005
Table 1. Categorization of CLN5 N-glycosylation sites.
N-glycosylation Residue(s) Function
Localization
(if lacking)
N179, N252, N304, N320, N330* Folding ER
N401 Trafficking Golgi**
N192, N227 Lysosomal function Lysosome
*some N330Q protein can be observed in the lysosome.
**N401Q mutant is temporarily accumulated in the Golgi and then secreted to
the media.
doi:10.1371/journal.pone.0074299.t001
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correctly localizes to the lysosome. Despite correct localization of
the CLN5 protein, the N192S mutation (the single mutation in
CLN5 found in this patient) [9] is enough to cause disease
manifestation. This suggests that glycosylation on N192 is a crucial
element for functionality of the CLN5 protein in the lysosomes.
Functional analysis for CLN5 will be needed to further assess the
role of glycosylation at this stage.
Supporting Information
Figur e S1 Alignment of mammalian CLN5 protein sequences
using CLUSTAL W2 program. The orange boxes with residue
number indicate conserved N-glycosylation sites among different
species, while the green box indicates the N-glycosylation site
corresponding to human N401, which is not conserved in rodents
such as M. musculus and R. norvegicus. The blue dotted line indicates
possible cleavage region by signal sequence peptidase. The red
asterisks with residue numbers indicate the patient mutants used in
this study. Sequences used in this alignment: H. sapiens
NP_006484, P. troglodytes XP_509687, B. taurus DAA23821, C.
familiaris NP_001011556, M. musculus AAI41315, and R. norvegicus
NP_001178618.
(TIF)
Figur e S2 Coomassie blue staining of full blots from main
Figs. 1, 2, 4, and 6. After immunoblotting, the membranes were
stained with Coomassie using the Sapphire Coomassie powder kit
Figure 6. Subcellular localization and stability of CLN5 patient mutations. Confocal microscopy analysis of cells transiently expressing
patient mutants of CLN5. (A) HeLa cells were double transfected using EGFP-Rab5A Q79L and D279N, Y392X or N192S. The cells were treated with
cycloheximide for 2 h prior to fixation. The mouse monoclonal anti-Myc antibody was used to detect CLN5. Original magnification, 1,0006 . Bars,
5 mm. (B) HeLa cells were transfected with patient mutants as indicated for 20 h after which cycloheximide chase was performed for 0, 2, and 4 h. Cell
pellets from 0, 2, and 4 h and medium samples from 2 and 4 h are shown. No samples were loaded in lanes labeled (2). The mouse monoclonal anti-
Myc antibody was used to detect CLN5.
doi:10.1371/journal.pone.0074299.g006
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(Gold Biotechnology) to show that equal amounts of samples were
loaded into each lane.
(TIF)
Figur e S3 Quantification and normalization of Western blot
signals presented in Figs. 5 and 6B. Western blots and Coomassie
stained blots (Fig. S2) were imaged using GeneSnap from Syngene
and quantified via densitometry using GeneTools analysis
software. Quantification used the rolling disk method with a
radius of 30 pixels and a Savitsky-Golay filter setting of 3. Samples
were normalized against loading densities measured from the
Coomassie stained blots as seen in formulas provided below. Cell
pellet samples were normalized against protein levels present in
the 0 hour time sample of the corresponding set, whereas the
medium samples were normalized against the 2 hour time sample
within the corresponding set. Values plotted in the graphs
represent averages and standard deviations calculated from at
least three biologically independent replicates. The y-axis
represents arbitrary density units (ADU) as measured by
GeneTools. The regions used in Coomassie blot densitometry:
cell pellet samples, covering two major bands around 46 KDa;
medium samples, covering one major band between 58 and
80 KDa that is present in the OPTI-MEM. Cell pellet samples
Density of Western at x hour
density of Coomassie at x hour=density of Coomassie at 0 hour    Medium sam-
ples Density of Western at x hourdensity of Coomassie at x hour=density of Coomassie at 2 hour   .
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